OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2022-03-31-accounts

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Annual Report and Accounts 31 March 2022

Company registration number 02908933 | Charity registration number 1040650

Contents

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Charity Information 1
Trustees’ Annual Report 2
Statement Of Directors’ Responsibilities 8
Independent Examiner’s Report 11

Funds Statements:

tatements:
Statement Of Financial Activities 13
Statement Of Financial Activities - Prior Year Statement 14
Statement Of Total Recognised Gains And Losses 15
Movements In Funds 16
Revenue Funds 16
Income And Expenditure Account 18
Balance Sheet 19

Notes To The Accounts 22

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Trustees’ Annual Report for the year ended 31 March 2022 charity information

The Trustees present their Report and Accounts for the year ended 31 March 2022, which also comprises the Directors’ Report required by the Companies Act 2006.

Charity Name

The legal name of the charity is: Bath Institute for Rheumatic Diseases.

The charity is also known by its operating name, BIRD.

The charity’s areas of operation and UK charitable registration.

The charity is registered with the Charity Commission in England & Wales (CCEW) with charity number 1040650.

The charity does not operate in any overseas jurisdictions.

Legal structure of the Charity

The charity is constituted as a company limited by guarantee, registered under the Companies Acts. The governing document of the charity is the Memorandum and Articles of Association establishing the company under company legislation.

The principal operating address, telephone number, email and web addresses of the charity are:

Department D1 Wolfson Building Royal United Hospital Bath BA1 3NG

Telephone: 01225 336363 Email Address: BIRD@birdbath.org.uk Web Address: www.birdbath.org.uk

The registered office of the charity for Companies Act purposes is the same as the operating address shown above.

The Trustees in Office on the Date the Report was Approved were:

Dr N Hall (resigned 29th April 2021) Mr C Johns (Chair) Ms S Lear (resigned 15th March 2022) Dr A Mackenzie Prof N McHugh Prof B Morley (appointed 25th May 2021) Dr J Pauling (resigned 15th March 2022) Dr R Sengupta Mr J Sherwin Dr W Tillett

The governing document is dated 24 November 2020.

There are no restrictions in the governing documents on the operation of the Charity or on its investment powers other than those imposed by Charity Law.

By operation of law all trustees are directors under the Companies Act 2006 and all directors are trustees under Charities legislation and have responsibilities, as such, under both company and charity legislation. The trustees are all individuals.

1

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Trustees’ Annual Report for the year ended 31 March 2022

Objects and Activities of the Charity

Bath Institute for Rheumatic Diseases (BIRD) is an incorporated charity. Its objectives, as set out in the Memorandum and Articles of Association, are to relieve sickness and to promote and advance medical knowledge with particular reference to rheumatic diseases; and to undertake research in relation thereto and to publish the useful results of such research. BIRD funds research and education into all areas of rheumatology and all types of bone and joint disorder.

Response to the continuing Covid pandemic and economic climate

The Covid 19 pandemic continued to shape BIRD’s operations during the period covered by this report. Most live events (patient engagement days and Education seminars for Healthcare Professionals, also the annual fundraising/awareness raising event) were cancelled and the office was closed. Consultant Trustees and other healthcare professionals on BIRD’s committees, undertaking research and acting as podcast and webinar speakers were extremely busy addressing the backlog in patients.

The education programme for consultants, GPs, nurses and physiotherapists was also partly delivered online. And staff continued to work mainly from home.

We finish the financial year £117,000 ahead of last year on total funds. Income was up by a third, due to fundraising efforts, and expenditure was reduced to 80% of previous year mainly because of an unintended reduction in grant giving (being dependent on the quality of grant applications we receive, not all make it through the approval process). There was also an exceptional credit item of £41,895 in the accounts, which represents a cancelled project grant and an underspend in a grant from a previous year. The growth in the value of our investments grew by £132,320.

Grants awarded for Research

BIRD funds research projects in rheumatic diseases which:

The focus is on pump prime funding for smaller projects, undertaken in or from Bath for the benefit of patients worldwide.

The guideline for grant amounts is up to £20,000 (but greater amounts may be considered) that would be ideally suited to pilot studies, preliminary research, tests of clinical effectiveness or would enable other grants to be made for research.

Recent evaluation of BIRD’s research grant programme since 2016 confirmed that it has achieved its intended functions of promoting and advancing medical science, pump-priming research, helping researchers in the early stages of their careers, helping clinicians to be research active, encouraging collaborations between clinicians and research scientists, and ensuring patients are involved in research.

Projects funded by BIRD are often highly collaborative, with researchers and clinicians working together to address challenges in rheumatic diseases.

Since 2016 BIRD has funded over 20 projects, with at least 20 published academic papers and 537 patients involved in a meaningful way, helping to advance medical science, with grants generating at least 20 academic publications so far.

In total, £55,047 was awarded:

2

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Trustees’ Annual Report for the year ended 31 March 2022

in her National Institute for Health Research Clinical Lectureship.

BIRD took forward the first phase of recommendations from the previous year’s research grant evaluation report by:

BIRD’s education programme for Healthcare Professionals

BIRD organised a wide-ranging programme for the continued education and training of healthcare professionals, working closely with a range of health and education providers, including the Royal United Hospital for Rheumatic Diseases, the University of Bath and the Bath GP Education & Research Trust.

The programme was attended by Consultants, Clinical Staff, Academic and Clinical Researchers, GPs, Nurse Practitioners and Primary Care Healthcare Professionals.

BIRD provided the administration, support, including the accreditation and sponsorship where necessary, for educational events reaching 357 healthcare professionals, significantly up from 254 last year and 300 the year before. Some face-to-face sessions, alongside online delivery were reinstated in hybrid sessions.

Each of the training sessions was approved for accreditation by either the Royal College of Physicians or the Bath GP Education & Research Trust (depending on whether the attendees came from primary or secondary care) which enabled them to gain continuing professional development credits.

Five Rheumatology Research group meetings were held, bringing together researchers at the University and clinicians at the hospital to update one another on two new projects at a time. This meeting was renamed Bath Inflammation and Immunology Research Group.

The South West CTD & Vasculitis Meeting was held on 21 September 2021.

The Regional South-West Osteoporosis Meeting was held on 16 November 2021.

The South West Axial Spondyloarthritis Group was held on 23 November 2021.

The Primary Care Rheumatology Update afternoon was held on 29 March 2022.

Qualitative feedback collected from some of the sessions showed that participants rated talks either ‘excellent’ or ‘good’ with most comments finding the training “helpful” and a useful update, eg “a good summary reminding me of salient topics” and “brilliant afternoon with varied and interesting presentations”. Participants had plenty of learning points to share with colleagues.

The Education Programme was led by Dr Andrew Allard, consultant rheumatologist, and Fran Staples, Senior Administrator BIRD.

3

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Trustees’ Annual Report for the year ended 31 March 2022

----- Start of picture text -----
?
----- End of picture text -----

The Patient and Public Engagement Programme

Our vision was restated during the year ‘to help more patients to be involved in research and deepen their understanding of Rheumatic Diseases, the latest research and treatment’. With twin aims of:

1. Patients have a deeper knowledge of Rheumatic Diseases, helping to lessen anxiety and increase confidence to self-manage and communicate with their healthcare professionals

2. Patients are involved in research, helping to inform and share the patient perspective with researchers to ensure the aims are true to need

Led by patient engagement expert Mel Brooke since 2016, the programme has continuously evolved and developed around patient audience needs. It provides opportunities for them to connect, learn and share through a flexible and innovative mix of media.

Podcasts covering a range of rheumatology conditions, these now reach thousands of patients and their families, across the country (and beyond) heavily promoted on social media. Over the year Mel Brooke produced 15 new podcasts bringing the library to 35 and achieving an amazing 3,950 listens. New topics covered were Osteoarthritis, Psoriatic Arthritis, Rheumatoid Arthritis, self-management and wellbeing topics of fatigue, sleep and social prescribing.

Webinars were introduced for the first time, providing live events online that give patients access to consultants and experts’ presentations and the opportunity to ask questions. 48 patients attended these first webinars.

Research - patients tell us they are keen to ‘give back’ and get involved in research, mainly through taking part in surveys and questionnaires circulated but also through focus groups, workshops and other participation. Over 2,600 patients were invited to

participate and 251 patients got involved in research during the year.

Patient Research Panel - 21 committed enthusiasts provided feedback on survey design and research opportunities to academic and clinical researchers during the year Patient centered culture We work hard to understand and accommodate patient needs and provide what is meaningful to them, through formative survey, feed back and involvement in the governance of BIRD. Two new cases studies were produced to tell patients’ stories.

Impacts

8,826 podcast listens in the two-year period April 2020 to April 2022

76% of listeners to podcasts understood their condition better as result

85 % reported increased confidence to live with their condition

85% felt empowered to make decisions about their treatments

75% reported that hearing voices of clinicians and healthcare practitioners was reassuring

58% reported the podcasts a help to their mental health - they felt supported, less isolated and part of a community

Patients said:

‘I learnt a great deal about my condition and about possible ways to help myself. I was able to recognise and adapt some of the wider potential impacts of life and health choices’

‘The more we as patients understand about Psoriatic Arthritis, the more effectively we can manage our condition’

‘All useful, especially identifying with fellow sufferers’

‘Everything was really interesting, educational and inspirational’

‘My main motivation to participate in research opportunities is to hopefully help future generations and the current understanding of rheumatic diseases’.

4

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Trustees’ Annual Report for the year ended 31 March 2022

Awareness raising

The reach of BIRD continued to expand through ongoing investment in Facebook advertising for the podcasts, with over 200,000 people getting the opportunity to see a BIRD advertisement for the podcasts.

Effort spent in seeking to attract grants from pharmaceutical companies for the Patient Engagement programme began to pay off, and resulted in £43,000 in grants and awards. This was largely due to the excellent performance of the podcasts and advertising them widely on social media, which attracted thousands of listeners.

In November 2021 BIRD was delighted to win the international Amgen UPLIFT Innovation Challenge worth $25,000 for its development of digital support for patients. Other pharmaceutical funders were Eli Lilly and Company Ltd and UCB.

76% of listeners to podcasts understood their condition better as result. 251 patients participated in research, and over 2,600 were invited to participate.

Awareness raising continued to grow through advertising, e-newsletter engagement and stakeholder relations with the University and Hospital.

Fundraising was greatly more than doubled, largely thanks to pharmaceutical grants but also thanks to the efforts of individuals.

Overall, the charity’s beneficiaries: scientific academia and patients, carers and their families benefited from better understanding of rheumatic diseases and their treatment, thereby contributing to the alleviation of suffering.

Further grants were awarded to the Patient and Public Engagement programme by the Champniss Charitable Trust, HealthWatch B&NES, Renishaw, The Saturday Hospital Fund, and the Siddons Charitable Trust.

Dr Ben Mulhearn ran the Palma half marathon and raised £1207 and a team of MBA students from the University of Bath raised £820 for BIRD’s research funds.

The main achievements and performance of the charity in terms of public benefit

The total amount of grants awarded for research into rheumatic diseases was £55,047 .

357 professionals attended BIRD training sessions, meetings and events for consultants, clinicians, healthcare professionals, researchers and academics.

3,950 listens to podcasts for patients and 511 registered for newsletters. The total network reached via mailings and social media ad postings was estimated at almost 200,000 patients and members of the public.

5

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Trustees’ Annual Report for the year ended 31 March 2022

Structure, governance and management of the charity

The governing body is the Council of Management made up of 9 trustees. The chair is Chris Johns. Council of Management meets quarterly.

Bankers

Unity Trust Bank, 9 Brindley Place, Birmingham, B1 2HB

CCLA Investment Management Ltd, COIF Charity Funds, Senator House, London

Three committees report in to the Council of Management. These are the quarterly Finance Committee, chaired by Jim Sherwin, members are Dr Linda McHugh, Chris Johns and Linda Snelus; the biannual Research Committee, chaired by Professor Bernie Morley emeritus, members are Professor Rod Flower, Ben Hutchinson, Dr Amanda MacKenzie, Professor Neil McHugh, Dr John Pauling, Dr Sarah Skeoch, Dr Paula Smith and Frank Sweeting; and the quarterly Education & Engagement Committee, chaired by Stephanie Lear, members are Dr Andrew Allard, Katie Burfitt, Judy Coles and Dr Patrick Ismond. All committees are supported by relevant contract staff in attendance.

Financial review

Royal London Asset Management, 55 Gracechurch Street, London

Solicitors

Stone King, 13 Queen Square, Bath, BA1 2HJ

Accountants

DR Hicks, Chartered Accountants, 107 Penn Hill Road, Bath, BA1 3RU

The Finance Committee, on behalf of Council ensured BIRD’s investments maximised the funds available for furthering BIRD’s charitable objectives. To this end costs were scrutinised and investment performance was reviewed quarterly alongside the operational management accounts.

The financial position of the charity at 31 March 2022 and comparatives for the prior period, as more fully detailed in the accounts, can be summarised as follows:-

Net income
Unrestricted Revenue Funds available for the general purposes of the charity
Designated Revenue Funds
Total Unrestricted Funds
Restricted Revenue Funds
Total Funds		 2022
£
117,107
1,778,291
21,513
1,799,804
19,701
1,819,505		 2021
£
172,928
1,667,587
14,666
1,682,253
20,145
1,702,398

6

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Trustees’ Annual Report for the year ended 31 March 2022

BIRD’s reserves policy is to

The board of trustees is satisfied that the charity’s assets in each fund are available and adequate to fulfil its obligations in respect of each fund.

The aim of the investment strategy is to provide sufficient income and capital growth to provide a total return above the rate of inflation, over time, such that a proportion can be used for research or to support the charitable aims, whilst at the same time maintaining the real value of the portfolio. The objective is a ‘balanced’ return between income and capital, at medium risk over a time horizon of ten years plus.

Both capital and income may be used at any time for the furtherance of the charity’s aims and therefore the portfolio is managed on a total return basis.

Ethical considerations: The ethical policy broadly follows that of the University of Bath. The trustees have precluded direct investment in tobacco. The trustees reserve the right to exclude companies that carry out activities contrary to their aims or from holding particular investments which damage the Charity’s reputation.

The objectives are to be achieved by investing prudently in a broad range of equities, fixed interest securities and collective vehicles (like unit trusts) which are appropriately authorised. Dividends and interest are paid away on a quarterly basis.

understand their disease and treatment better and, with renewed focus, hundreds to engage with research. It will also continue to maintain and develop the education programme for healthcare professionals.

The Patient Engagement programme will continue to evolve, as digital offerings develop and ways to help patients get involved in research develop. The programme will also seek to help researchers work with patients. Ongoing evaluation and patient input will shape the programme, through the patient research panel, the patient listening panel and through surveys and feedback.

The long-term intention remains to balance reliance on investment performance with more grant and donor fundraising, which itself requires a raised profile and clearer articulation of impact. BIRD will work on a strategy to achieve that during the year ahead.

Next year BIRD will undertake a recruitment exercise for new Trustees and committee members as part of good succession planning.

Details of The Independent Examiner

Tom Case Member of The Institute of Chartered Accountants in England and Wales 20 Goodwood Way Cepen Park South Chippenham Wiltshire SN14 0SY

Summary of plans for the future

BIRD remains committed to funding research into rheumatic diseases, through pump-prime funding of around £80,000, depending on the quality of applications received and will encourage clinicians to undertake research and early stage career researchers. It will help thousands of patients to

7

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Trustees’ Annual Report for the year ended 31 March 2022

Statement of the Directors’ and Trustees’ Responsibilities

The charity’s trustees are responsible for the preparation of the accounts in accordance with the terms of the Companies Act 2006, the Charities Act 2011 and the Charities (Accounts and Reports) Regulations 2008. Notwithstanding the explicit requirement in the extant statutory regulations,the Charities (Accounts and Reports) Regulations 2008, to prepare the financial statements in accordance with the SORP 2005, in view of the fact that the SORP 2005 has been withdrawn, the Trustees determined to interpret this responsibility as requiring them to follow current best practice and prepare the accounts according to the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP),

In particular, the Companies Act 2006 and charity law require the Board of Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity as at the end of the financial year and of the surplus or deficit of the charity. In preparing those financial statements the Board is required to :-

The law requires that the trustees must not approve the accounts unless they are satisfied that they give a true and fair view of the state of affairs of the charity and of the surplus or deficit of the charity for the year.

The Trustees are also responsible for maintaining adequate accounting records which disclose with reasonable accuracy at any time the financial position of the charity and which are sufficient to show and explain the charity’s transactions and enable them to ensure that the financial statements comply with the Companies Act 2006 and comply with regulations made under the Charities Act. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are also responsible for the contents of the Trustees’ report, and the statutory responsibility of the Independent Examiner in relation to the Trustees’ report is limited to examining the report and ensuring that, on the face of the report, there are no material inconsistencies with the figures disclosed in the financial statements.

Method of preparation of accounts - Small company provisions

The financial statements are set out on pages 13-19.

The financial statements have been prepared implementing the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), and in accordance with the Financial Reporting Standard 102, (effective 1st January 2016).

8

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Trustees’ Annual Report for the year ended 31 March 2022

These financial statements have been prepared in accordance with the provisions in Part 15 of the Companies Act 2006. applicable to companies subject to the small companies regime.

This report was approved by the board of trustees on 20 September 2022.

Christopher Johns, Chair

9

Report of the Independent Examiner to the Trustees of the charitable company on the accounts for the year ended 31 March 2022

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Report of the Independent Examiner to the Trustees of the charitable company on the accounts for the year ended 31 March 2022

I report to the Trustees on my examination of the financial statements of the charitable company on pages 13 to 19 for the year ended 31 March 2022 which have been prepared in accordance with the Charities Act 2011 (the Act) and with the Financial Reporting Standard 102, (effective 1st January 2016) as modified by FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), published by the Charity Commission in England & Wales (CCEW) , and under the historical cost convention and the accounting policies set out on page 22.

Respective responsibilities of the Trustees and the Independent Examiner and the basis of the report

As described on page 1, you, the charitable company’s Trustees, who are also the Directors of the Company for the purposes of Company law, are responsible for the preparation of the financial statements in accordance with the Companies Act 2006, the Charities Act 2011 and all other applicable law and with United Kingdom Generally Accepted Accounting Practice, applicable to smaller entities, and for being satisfied that the financial statements give a true and fair view.

The Trustees consider that the audit requirement of Section 144(1) of the Charities Act 2011 (the Act) does not apply, and that there is no requirement in the memorandum and articles of the charity for the conducting of an audit, and that the accounts do not require an audit in accordance with Part 16 of the Companies Act 2006 and that no member or members have requested an audit pursuant to Section 476 of the Companies Act 2006. As a consequence, the Trustees have elected that the financial statements be subject to independent examination.

Having satisfied myself that the financial statements are not required to be audited under any legal provision, or otherwise, and are eligible for independent examination, it is my responsibility to:-

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

I report in respect of my examination of the charity’s financial statements carried out under s145 of the Act. In carrying out my examination, I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act setting out the duties of an independent examiner in relation to the conducting of an independent examination. An independent examination includes a review of the accounting records kept by the charitable company and of the accounting systems employed by the charitable company and a comparison of the financial statements presented with those records. It also includes consideration of any unusual items or disclosures in the financial statements, and seeking explanations from you, as Trustees, concerning such matters. The purpose of the examination is to establish as far as possible that there have been no breaches of charity legislation and that, on a test basis of evidence relevant to the amounts and disclosures made, the financial statements comply with the SORP.

The procedures undertaken do not provide all the evidence that would be required in an audit, and information supplied by the Trustees in the course of the examination is not subjected to audit tests or enquiries and does not cover all the matters that an auditor would consider in arriving at an opinion. The planning and conduct of an audit goes beyond the limited assurance that an independent examination can provide. Consequently, I do not express an audit opinion on the view given by the financial statements, and in particular, I express no opinion as to whether the financial statements give a true and fair view of the affairs of the charity, and my report is limited to the matters set out in the statement below.

I planned and performed my examination so as to satisfy myself that the objectives of the independent examination are achieved and before finalising the report I obtained written assurances from the Trustees of all material matters.

11

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Report of the Independent Examiner to the Trustees of the charitable company on the accounts for the year ended 31 March 2022

Independent Examiner’s Statement, Report and Opinion

Subject to the limitations upon the scope of my work as detailed above, I have completed my examination: and can confirm that:-

No material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:-

Signed:

Mr Tom Case, Independent Examiner

The Institute of Chartered Accountants in England and Wales

20 Goodwood Way Cepen Park South Chippenham Wiltshire SN14 0SY

This report was signed on 20 September 2022.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.

12

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Statement of Financial Activities for the year ended 31 March 2022

SORP
Ref
Income & Endowments from:
Donations & Legacies
A1
Charitable activities
A2
Investments
A4
Total income
A
Expenditure on:
Charitable activities
B2
Total expenditure
B
Net gains on investments
B4
Net income for the year
Transfers between funds
C
Net income after transfers
A-B-C
Extraordinary items
D3
Net movement in funds
Reconciliation of funds:-
E
Total funds brought forward
Total funds carried forward		 Current year
Unrestricted
Funds
2022
£
55,858
20,579
47,199
123,636
180,300
180,300
132,320
75,656
-
75,656
41,895
117,551
1,682,253
1,799,804		 Current year
Restricted
Funds
2022
£
-
150
-
150
594
594
-
(444)
-
(444)
-
(444)
20,145
19,701		 Current year
Total Funds
2022
£
55,858
20,729
47,199
123,786
180,894
180,894
132,320
75,212
-
75,212
41,895
117,107
1,702,398
1,819,505		 Prior Year
Total Funds
2021
£
20,340
23,064
49,315
92,719
224,733
224,733
304,942
172,928
-
172,928
-
172,928
1,529,470
1,702,398

The ‘SORP Ref’ indicated above is the classification of income set out in the formal SORP documents. As required by paragraph 4.60 of the SORP, the brought forward and carried forward funds above have been agreed to the Balance Sheet.

A Statement of Total Recognised Gains and Losses is included as a primary statement in these accounts.

All activities derive from continuing operations. The notes attached on pages 22 to 41 form an integral part of these accounts.

13

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Statement of Financial Activities for the year ended 31 March 2022

Analysis of prior year total funds as required by paragraph 4.2 of the SORP.

SORP REF
Income & Endowments from:
Donations & Legacies
A1
Charitable activities
A2
Investments
A4
Total income
A
Expenditure on:
Charitable activities
B2
Total expenditure
B
Net gains on investments
B4
Net income for the year
Transfers between funds
C
Net income after transfers
Net movement in funds
Reconciliation of funds:-
E
Total funds brought forward
Total funds carried forward		 Prior Year
Unrestricted
Funds
2021
£
20,340
22,449
49,315
92,104
223,799
223,799
304,942
173,247
2,085
175,332
175,332
1,506,921
1,682,253		 Prior Year
Restricted
Funds
2021
£
-
615
-
615
934
934
-
(319)
(2,085)
(2,404)
(2,404)
22,549
20,145		 Prior Year
Total Funds
2021
£
20,340
23,064
49,315
92,719
224,733
224,733
304,942
172,928
-
172,928
172,928
1,529,470
1,702,398

All activities derive from continuing operations.

A Statement of Total Recognised Gains and Losses is included in these accounts as a separate primary statement.

The notes attached on pagesv form an integral part of these accounts.

14

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Statement of Financial Activities for the year ended 31 March 2022

Statement of Total Recognised Gains and Losses for the year ended 31 March 2022

(Deficit)/Surplus for the year :-
Net excess of income over expenditure from operations before tax
Income from operations before tax in the Statement of Financial Activities
Realised (losses)/gains on investments
Extraordinary items
Surplus as shown in the Income and Expenditure account
Unrealised (losses)/gains on investments
Net Movement in funds before taxation
Funds generated in the year as shown on Statement of Financial Activities		 2022
£
(57,108)
-
(57,108)
(2,104)
41,895
(17,317)
134,424
117,107
117,107		 2021
£
(132,014)
-
(132,014)
16,967
-
(115,047)
287,975
172,928
172,928

Resources applied in the year ended 31 March 2022 towards fixed assets for Charity use

Funds generated in the year as detailed in the SOFA
Resources applied on functional fixed assets
Net resources available to fund charitable activities		 2022
£
117,107
-
117,107		 2022
£
172,928
(1,260)
171,668

15

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Statement of Financial Activities for the year ended 31 March 2022

Resources applied in the year ended 31 March 2022 towards fixed assets for Charity use

Revenue accumulated funds
Accumulated funds brought forward
Recognised gains and losses before
transfers
Extraordinary items
Closing revenue funds		 Unrestricted
Funds
2022
£
1,682,253
75,656
1,757,909
41,895
1,799,804		 Restricted
Funds
2022
£
20,145
(444)
19,701
-
19,701		 Total
Funds
2022
£
1,702,398
75,212
1,777,610
41,895
1,819,505		 Last year
Total Funds
2021
£
1,529,470
172,928
1,702,398
-
1,702,398

Designated revenue funds included within the unrestricted funds above

At 1 April
Transfer (to)/from revenue accumulated funds
At 31 March		 Total
Funds
2022
£
14,666
6,847
21,513		 Last year
Total Funds
2021
£
14,595
71
14,666

The purposes for which these funds have been designated are described in Note 22 to the accounts.

16

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Statement of Financial Activities for the year ended 31 March 2022

Summary of funds

Revenue accumulated funds
Revenue designated funds
Total funds		 Unrestricted
and Designated Funds
2022
£
1,778,291
21,513
1,799,804		 Restricted
Funds
2022
£
19,701
-
19,701		 Total
Funds
2022
£
1,797,992
21,513
1,819,505		 Last Year
Total Funds
2021
£
1,687,732
14,666
1,702,398

The notes attached on pages 22 to 41 form an integral part of these accounts.

17

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Statement of Financial Activities for the year ended 31 March 2022

Income and Expenditure Account for the year ended 31 March 2022 as required by the Companies Act 2006

Income
Income from operations
Realised gains/(losses) on investments
Investment income
Income from investments, other than interest receivable
Gross income in the year before exceptional items		 2022
£
76,587
-
47,199
123,786
123,786
180,180
276
438
2,104
182,998
41,895
(17,317)
-
(17,317)
(17,317)		 2021
£
43,404
16,967
49,315
109,686
Gross income in the year including exceptional items 109,686
Expenditure
Charitable expenditure, excluding depreciation and amortisation
Depreciation and amortisation
Governance costs
Realised losses on the disposal of investments
Total expenditure in the year
Extraordinary items
Net income before tax in the financial year
Tax on surplus on ordinary activities
Net income after tax in the financial year
Retained surplus for the financial year		 223,984
329
420
-
224,733
-
(115,047)
-
(115,047)
(115,047)

All activities derive from continuing operations.

The notes attached on pages 22 to 41 form an integral part of these accounts.

In accordance with the provisions of the Companies Act 2006, the headings and subheadings used in the Income and Expenditure account have been adapted to reflect the special nature of the charity’s activities.

18

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Balance Sheet as at 31 March 2022

Note SORP 2022 2021
Ref
£ £
Fixed assets A
Tangible assets 11 A2 943 1,219
Investments held as fixed assets 12 A4 1,736,569 1,602,145
Total fixed assets 1,737,512 1,603,364
Current assets B
Debtors 14 B2 18,284 9,798
Cash at bank and in hand B4 151,545 259,598
Total current assets 169,829 269,396
Creditors: amounts falling due within one year 15 C1 (87,836) (170,362)
Net current assets 81,993 99,034
The total net assets of the charity 1,819,505 1,702,398
The total net assets of the charity are funded by the funds of the charity, as follows:-
Restricted funds
Restricted Revenue Funds 19 D2 19,701 20,145
19,701 20,145
Unrestricted Funds
Unrestricted Revenue Funds 19 D3 1,778,291 1,667,587
1,778,291 1,667,587
Designated Funds
Designated Revenue Funds 19 D3 21,513 14,666
21,513 14,666
Total charity funds 1,819,505 1,702,398

19

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Balance Sheet as at 31 March 2022

The ‘SORP Ref’ indicated above is the classification of Balance Sheet items as set out in the formal SORP documents. As required by paragraph 4.60 of the SORP, the brought forward and carried forward funds above have been agreed to the SOFA.

The directors are satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.

The members have not required the company to obtain an audit in accordance with section 476 of the Act.

The financial statements have been prepared in accordance with the provisions in Part 15 of the Companies Act 2006 applicable to companies subject to the small companies regime.

Mr JT Sherwin

Trustee and Chair of Finance Committee Approved by the board of trustees on 20 September 2022.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.

The charity is subject to Independent Examination under charity legislation, and the report of the Independent Examiner is on page 11.

20

Bath Institute for Rheumatic DiSea5eS Supporting Arthritis Research in Bath Re8iStered Charity 1040650 01225 336363 BIRD@blrdbath.org. I Insfl m4flc I

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Notes to the Accounts for the year ended 31 March 2022

1. Accounting Policies Policies Relating to the Production of the Accounts

Basis of Preparation and Accounting Convention

The accounts have been prepared on the accruals basis, under the historical cost convention, and in accordance with the Financial Reporting Standard 102, (effective 1st January 2016) and ‘FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), published by the Charity Commission in England & Wales (CCEW) , effective January 2016, , and in accordance with all applicable law in the charity’s jurisdiction of registration, except that the charity has prepared the financial statements in accordance with the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), in preference to the previous SORP, the SORP 2005, which has been withdrawn, notwithstanding the fact that the extant statutory regulations, the Charities (Accounts and Reports) Regulations 2008 refer explicitly to the SORP 2005. This has been done to accord with current best practice.

Going Concern

The Trustees are satisfied that, at the time of approving the financial statements, it is appropriate to adopt the going concern basis in preparing the financial statements. The Trustees are not aware of any material uncertainties about the charity’s ability to continue as a going concern.

Policies relating to categories of income and income recognition

Nature of Income

Gross income represents the value, net of value added tax and discounts, of goods provided to customers and work carried out in respect of services provided to customers.

Categories of Income

Income is categorised as income from exchange transactions (contract income) and income from nonexchange transactions (gifts), investment income and other income.

Income from exchange transactions is received by the charity for goods or services supplied under contract or where entitlement is subject to fulfilling performance related conditions. The income the charity receives is approximately equal in value to the goods or services supplied by the charity to the purchaser.

Income from a non-exchange transaction is where the charity receives value from the donor without providing equal value in exchange, and includes donations of money, goods and services freely given without giving equal value in exchange.

Income Recognition

Income, whether from exchange or non exchange transactions, is recognised in the statement of financial activities (SOFA) on a receivable basis, when a transaction or other event results in an increase in the charity’s assets or a reduction in its liabilities and only when the charity has legal entitlement, the income is probable and can be measured reliably.

Risks and Future Assumptions

BIRD meets the definition of a public benefit entity under FRS102. Assets and liabilities are initially recognised at historical cost or transaction value unless stated in the relevant accounting policy note(s).

Dividends are accrued when the shareholder’s right to receive payment is established.

Income subject to terms and conditions which must be met before the charity is entitled to the resources is not recognised until the conditions have been met.

22

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Notes to the Accounts for the year ended 31 March 2022

Income from Legacies

Income from legacies is recognised when the charity has sufficient evidence that a gift has been left to them, that where required, probate has been granted, the executor is satisfied that the property in question will not be required to satisfy claims in the estate, that it is probable that the amount will be received by the charity, and the amount to be received can be estimated with sufficient accuracy, and that any conditions attached to the legacy are either within the control of the charity or have been met.

Where a payment is received from an estate or is notified as receivable by the executors after the reporting date and before the accounts are authorised for issue but it is clear that the payment had been agreed by the executors prior to the end of the reporting period, then the amount concerned is treated as an adjusting event and accrued as income in the accounting period if receipt is probable.

Where the charity has established entitlement to a legacy but there is uncertainty as to the amount of the payment, details of the legacy are disclosed as a contingent asset until the criteria for income recognition are met. Where a legacy is subject to the interest of a life tenant, the legacy is not recognised as income until the death of the life tenant.

If it is doubtful that full settlement of a legacy debtor will be received, then an adjustment is made to reduce the amount of the legacy debtor and legacy income rather than charging the adjustment as expenditure in the Statement of Financial Activities.

Policies relating to expenditure on goods and services provided to the charity.

Liabilities arising from future funding commitments and constructive obligations, including performance related grants, where the timing or the amount of the future expenditure required to settle the obligation are uncertain, give rise to a provision in the accounts, which is reviewed at the accounting year end. The provision is increased to reflect any increases in liabilities, and is decreased by the utilisation of any provision within the period, and reversed if any provision is no longer required. These movements are charged or credited to the respective funds and activities to which the provision relates.

Policies relating to assets, liabilities and provisions and other matters.

Fixed Asset Investments

Fixed asset investments in quoted shares, traded bonds, investment properties and similar investments are shown initially at cost upon acquisition and at their market value at the balance sheet date at the end of the financial period. Investment properties are not depreciated.

Fixed asset investments in unlisted equities are shown at the balance sheet date at the best estimate of their market value, where practicable. Where valuation techniques are considered unreliable or where, in the opinion of the trustees, the costs outweigh the benefits to the users of the accounts, the investment is included at cost, and a review is undertaken at each year end as to whether the asset should be written down.

All gains on fixed asset investments, whether realised or unrealised, are included in row B4 of the Statement of Financial Activities.

Recognition of Liabilities and Expenditure

A liability, and the related expenditure, is recognised when a legal or constructive obligation exists as a result of a past event, and when it is more likely than not that a transfer of economic benefits will be required in settlement, and when the amount of the obligation can be measured or reliably estimated.

23

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Notes to the Accounts for the year ended 31 March 2022

Tangible Fixed Assets

Tangible fixed assets are measured at their original cost value, or subsequent revaluation, or if donated, as described above. Cost value includes all costs expended in bringing the asset into its intended working condition.

Depreciation has been provided at the following rates in order to write off the assets to their anticipated residual value over their estimated useful lives.

Plant and machinery - 20 % reducing balance.

Stocks and work in progress

Stock is valued at the lower of cost and net realisable value.

Debtors

Debtors are measured at their recoverable amounts at the balance sheet date.

Creditors and provisions

Liabilities are recognised on the accruals basis in accordance with normal accounting principals, modified where necessary in accordance with the guidance given in the SORP.

Financial Instruments Including Cash and Bank Balances

Cash held by the charity is included at the amount actually held and counted at the year end. Bank balances, whether in credit or overdrawn, are shown at the amounts properly reconciled to the bank statements.

2. Liability to Taxation

The Trustees consider that the charity satisfies the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 for UK corporation tax purposes. Accordingly, the Charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by chapter 3 part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively on the specific charitable objects of the charity and for no other purpose. Value Added Tax is not recoverable by the charity, and is therefore included in the relevant costs in the Statement of Financial Activities.

3. Winding up or Dissolution of the Charity

If upon winding up or dissolution of the charity there remain any assets, after the satisfaction of all debts and liabilities, the assets represented by the accumulated fund shall be transferred to some other charitable body or bodies having similar objects to the charity.

4. Significance of Financial Instruments to the Charity’s Position

There are no significant implications of financial instruments to the charity’s financial position or performance.

5. Net Surplus Before Tax in the Financial Year

The net surplus before tax in the financial year is stated after charging. Depreciation of owned fixed assets:

2022 = £276 2021 = £329

Fund Accounting

Unrestricted funds are available for use at the discretion of the trustees in furtherance of the general objectives of the charity.

Designated funds are unrestricted funds earmarked by the Trustees for particular purposes. Restricted funds are subjected to restrictions on their expenditure imposed by the donor or through the terms of an appeal or as implied by law. There are no endowment funds.

24

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Notes to the Accounts for the year ended 31 March 2022

6. Investment Gains

Current Year
Realised gains/(losses)
Listed investments
Total realised gains/(losses)
Unrealised gains /(losses) and writing down of
carrying values
Listed investments - Unrealised
Total unrealised gains/(losses) etc
Total realised and unrealised gains		 Current year
Unrestricted
Funds
2022
£
(2,104)
(2,104)
134,424
134,424
132,320		 Current year
Restricted
Funds
2022
£
-
-
-
-
-		 Current year
Total Funds
2022
£
(2,104)
(2,104)
134,424
134,424
132,320		 Prior Year
Total Funds
2021
£
16,967
16,967
287,975
287,975
304,942

All gains and losses in the prior year was unrestricted.

Prior Year:-

Realised gains/(losses)
Listed investments
Total realised gains/(losses)
Unrealised gains /(losses) and writing down of carrying values
Listed investments - Unrealised
Total unrealised gains/(losses) etc
Total realised and unrealised gains		 Prior Year
Unrestricted
Funds
2021
Prior Year
Restricted
Funds
2021
£
£
16,967
-
16,967
-
287,975
-
287,975
-
304,942
-		 Prior Year
Total Funds
2021
£
16,967
16,967
287,975
287,975
304,942

25

Notes to the Accounts for the year ended 31 March 2022

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

7. Extraordinary items - analysed by fund

This item comprises £23,085 of a cancelled grant from
previous years and £18,810 of an underspend from
the funded clinical lectureship finishing earlier than
awarded, due to promotion.
8. Staf costs and emoluments
2022
£
Unrestricted funds
(41,895)
Restricted funds
-
Total extraordinary items
(41,895)
(41,895)
Labour costs
2022
£
Gross salaries, labour and related costs
99,490
99,490		 2021
£
-
-
2021
£
111,081
111,081

Neither the trustees nor any persons connected with them have received any remuneration from the charity or any related entity, either in the current or prior year.

No employees received emoluments (excluding pension costs) in excess of £60,000 per annum.

9. Remuneration and payments to Trustees and persons connected with them

No trustees or persons connected with them received any remuneration from the charity, or any related entity.

26

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Notes to the Accounts for the year ended 31 March 2022

10. Trustee’s expenses

No trustee expenses were incurred, either in the current or prior year.

11. Tangible fixed assets

No trustee expenses were incurred, either in the current or prior year.

Current Year
Cost
At 1 April 2021
Additions
At 31 March 2022
Depreciation
At 1 April 2021
Charge for the year
At 31 March 2022
Net book value
At 31 March 2022
At 31 March 2021		 Land and
Buildings
£
-
-
-
-
-
-
-
-		 Plant &
Machinery
£
11,940
-
11,940
10,721
276
10,997
943
1,219		 Motor
Vehicles
£
-
-
-
-
-
-
-
-		 Total
£
11,940
-
11,940
10,721
276
10,997
943
1,219

12. Investments Held as Fixed Assets

Carrying values of investments
At 1 April 2021
Revaluation at 31 March 2022
At 31 March 2022
Analysis between fair value and historical cost
Investments as above held at fair value		 Investments in
subsidiaries
£
2
-
2
2		 Listed
investments
£
1,602,143
134,424
1,736,567
1,736,567		 Other Classes
of Investment
£
-
-
-
-		 Total
£
1,602,145
134,424
1,736,569
1,736,569

27

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Notes to the Accounts for the year ended 31 March 2022

13. Subsidiary companies

The name of the subsidiary undertaking is Bath Institute for Rheumatic Diseases Trading Limited, registered in England & Wales with company number 2602509.

The aggregate amount of the holding company’s investment in its subsidiary is £2, which represents 100% of the issued ordinary share capital of the subsidiary. The subsidiary is controlled by the holding company by virtue of the power to appoint directors to the board of the subsidiary.

The subsidiary’s activities relate to those of the holding company in that the subsidiary is a trading enterprise engaging in trades similar to the charitable activities of the holding company, and donates its entire taxable trading profit to the holding company by way of gift aid. The subsidiary has been dormant for the seven years ending 31st March 2022.

A summary of the unaudited financial statements of the subsidiary is :-

Assets and Funds
Aggregate amount of assets
Aggregate amounts of liabilities
Aggregate amount of funds
Profit and Loss
Net profit for the year before tax
Net profit for the year after tax and Gift Aid
Funds retained within charitable subsidiaries
The funds retained within the trading subsidiary and included
within the restricted funds in the notes to these accounts are:-		 2022
£
(231)
(316)
(547)
-
-
2022
£
-		 2021
£
(231)
(316)
(547)
-
-
2021
£
-

28

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Notes to the Accounts for the year ended 31 March 2022

14. Debtors

Trade debtors
Prepayments and accrued income		 2022
£
6,812
11,472
18,284		 2021
£
6,851
2,947
9,798

15. Creditors: amounts falling due within one year

Trade creditors
Accruals
Other creditors		 2022
£
29,191
600
58,045
87,836		 2021
£
29,859
600
139,903
170,362

16. Income and Expenditure account summary

At 1 April 2021
Surplus after tax for the year
At 31 March 2022		 2022
£
1,414,423
(17,317)
1,397,106		 2021
£
1,529,470
(115,047)
1,414,423

17. No related party transactions

There were no transactions with related parties in the year.

29

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Notes to the Accounts for the year ended 31 March 2022

18. Particulars of How Particular Funds are Represented by Assets and Liabilities

At 31 March 2022
Tangible Fixed Assets
Investments at valuation:-
Fixed asset investments
Current Assets
Current Liabilities
At 1 April 2021
Tangible Fixed Assets
Investments at valuation:-
Fixed asset investments
Current Assets
Current Liabilities		 Unrestricted
funds
£
943
1,736,569
128,615
(87,836)
1,778,291
Unrestricted
funds
£
1,219
1,602,145
234,585
(170,362)
1,667,587		 Designated
funds
£
-
-
21,513
-
21,513
Designated
funds
£
-
-
14,666
-
14,666		 Restricted
funds
£
-
-
19,701
-
19,701
Restricted
funds
£
-
-
20,145
-
20,145		 Total
funds
£
943
1,736,569
169,829
(87,836)
1,819,505
Total
funds
£
1,219
1,602,145
269,396
(170,362)
1,702,398

30

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Notes to the Accounts for the year ended 31 March 2022

19. Change in total funds over the year as shown in Note 18, analysed by individual funds

Unrestricted and designated funds:-
Unrestricted Revenue Funds
Designated Revenue Funds
Total unrestricted and designated funds
Restricted funds:-
Restricted - CRPS Conference
Restricted - CRPS Network UK
Restricted - Bone and Joint
Restricted - Arthritis Grand Challenge
Restricted - Metabolic Bone Disease
Total restricted funds
Total charity funds		 Funds brought
forward from
2021
£
1,667,587
14,666
1,682,253
1,121
1,691
14,145
67
3,121
20,145
1,702,398		 Movement in
funds in
2022
See Note 20
£
117,551
-
117,551
-
(594)
-
-
150
(444)
117,107		 Transfers
between funds
in 2022
See Note 21
£
(6,847)
6,847
-
-
-
-
-
-
-
-		 Funds carried
forward to
2023
£
1,778,291
21,513
1,799,804
1,121
1,097
14,145
67
3,121
19,701
1,819,505

31

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Notes to the Accounts for the year ended 31 March 2022

20. Analysis of movements in funds over the year as shown in Note 19

Unrestricted and designated funds:-
Unrestricted Revenue Funds
Restricted funds:-
Restricted - CRPS Network UK
Restricted - Metabolic Bone Disease		 Income
2022
£
123,636
150
123,786		 Expenditure
2022
£
(180,300)
(594)
-
(180,894)		 Other
Gains & Losses
2022
£
174,215
-
-
174,215		 Movement in
funds 2022
£
117,551
(594)
150
117,107

21. Details of transfers between

The transfers shown in note 18 above are:-
To/(from) Unrestricted Revenue Funds in accordance with the accounting policy
‘Accounting for capital grants and fixed asset funds’.
To/(from) Designated Revenue Funds
To/(from) Restricted Revenue Funds
Net transfers		 2022
£
(6,847)
6,847
-
-

22. The purposes for which the funds

Unrestricted Revenue Funds

These funds are held for the meeting the objectives of the charity, and to provide reserves for future activities, and , subject to charity legislation, are free from all restrictions on their use.

Designated Revenue Funds

Funds specific for this purpose.

Restricted Revenue Funds

Funds specific for this purpose.

32

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Notes to the Accounts for the year ended 31 March 2022

23. Ultimate controlling party

The charity is under the control of its legal members. Every member of the charity is obliged to contribute such amount as may be required not exceeding £1 to the assets of the company in the event of its being wound up while he or she is a member, or within one year after he or she ceases to be a member.

33

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Detailed analysis of income and expenditure for the year ended 31 March 2022 as required by the SORP 2015

24. Donations, Grants and Legacies

Donations and gifts from individuals
Donations
Total donations and gifts from individuals
Legacies receivable
Legacies receivable
Total legacies receivable
Total Donations, Grants and Legacies
A1		 Current year
Unrestricted
Funds
2022
£
55,858
55,858
Current year
Unrestricted
Funds
2022
£
-
-
55,858		 Current year
Restricted
Funds
2022
£
-
-
Current year
Restricted
Funds
2022
£
-
-
-		 Current year
Total Funds
2022
£
55,858
55,858
Current year
Total Funds
2022
£
-
-
55,858		 Prior Year
Total Funds
2021
£
19,783
19,783
Prior Year
Total Funds
202
£
557
557
20,340

34

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Detailed analysis of income and expenditure for the year ended 31 March 2022 as required by the SORP 2015

25. Income from charitable activities - Trading Activities

Prior year
Primary purpose and ancillary trading
Other and recharged income
Total Primary purpose and ancillary trading
Current year
Primary purpose and ancillary trading
Education income
Other and recharged income
Service charges - BGPERT
Service charges - BRIT PACT
Total Primary purpose and ancillary trading
Not all the trading activities in the prior year were
unrestricted.		 Current year
Unrestricted
Funds
2022
£
625
3,465
11,723
4,766
20,579		 Prior Year
Unrestricted
Funds
2021
£
60
22,449
Current year
Restricted
Funds
2022
£
-
150
-
-
150		 Prior Year
Restricted
Funds
2021
£
615
615
Current year
Total Funds
2022
£
625
3,615
11,723
4,766
20,729		 Prior Year
Total funds
2021
£
341
675
17,975
4,073
23,064
Prior Year
Total Funds
2021
£
675
23,064

35

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Detailed analysis of income and expenditure for the year ended 31 March 2022 as required by the SORP 2015

26. Total Income from charitable activities

Current year
Current year
Unrestricted
Funds
2022
£
Total income from charitable trading
20,579
Total from charitable activities
A2
20,579
Not all the income in the prior year was
unrestricted.
Prior year
Total income from charitable trading
Income from funders
Income from charitable activities - Prior Year analysis		 Current year
Restricted Funds
2022
£
150
150
Prior Year
2021
£
22,449
-
22,449		 Current year
Total Funds
2022
£
20,729
20,729
Prior Year
2021
£
615
-
615		 Prior Year
Total Funds
2021
£
23,064
23,064
Prior Year
2021
£
23,064
-
23,064

36

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Detailed analysis of income and expenditure for the year ended 31 March 2022 as required by the SORP 2015

27. Investment income

Dividend Income
Total investment income A4		 Current year
Unrestricted
Funds
2022
£
47,199
47,199		 Current year
Restricted
Funds
2022
£
-
-		 Current year
Total Funds
2022
£
47,199
47,199		 Prior Year
Total funds
2021
£
49,315
49,315

28. Expenditure on charitable activities - Direct spending

Current year
Labour costs - charitable activities
Education costs
PPE Project costs
Travel and conferences
Total direct spending
B2a
Not all the income in the prior year was
unrestricted.
Prior year
PPE Project costs
Total direct spending		 Current year
Unrestricted
Funds
2022
£
99,490
1,042
4,709
-
105,241
B2a		 Current year
Restricted
Funds
2022
£
-
-
-
-
-
Prior Year
2021
£
4,189
115,420		 Current year
Total
Funds
2022
£
99,490
1,042
4,709
-
105,241
Prior Year
2021
£
-
-		 Prior Year
Total
Funds
2021
£
111,081
-
4,189
150
115,420
Prior Year
2021
£
4,189
115,420

37

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Detailed analysis of income and expenditure for the year ended 31 March 2022 as required by the SORP 2015

29. Expenditure on charitable activities - grant funding of activities

Current year
Grants made to individuals
Grant underspends from prior years
Total grantmaking costs
B2c		 Current year
Unrestricted
Funds
2022
£
55,047
-
55,047		 Current year
Restricted
Funds
2022
£
-
-
-		 Current year
Total
Funds
2022
£
55,047
-
55,047		 Prior Year
Total
Funds
2021
£
78,688
-
78,688

38

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Detailed analysis of income and expenditure for the year ended 31 March 2022 as required by the SORP 2015

30. Support costs for charitable activities

Current Year
Premises Expenses
Rent
Administrative overheads
Telephone, fax and internet
Stationery and printing
Marketing and promotion
Registration and licensing
IT support costs
Sundry expenses
Recharged expenses
Insurance
Hospitality
Professional fees paid to advisors other than
the auditor or examiner
Accountancy fees other than examination or audit
fees
Other legal and professional
Financial costs
Bank charges
Investment management costs
Depreciation & Amortisation in total for the period
Support costs before reallocation
Total support costs - Current Year		 Current year
Unrestricted
Funds
2022
£
5,550
720
409
1,174
657
1,288
168
4,119
439
57

3,060
1,497
160
-
276
19,574
19,574		 Current year
Restricted
Funds
2022
£
-
-
-
-
-
-
-
594
-
-
-
-
-
-
-
594
594		 Current
year Total
Funds
2022
£
5,550
720
409
1,174
657
1,288
168
4,713
439
57
3,060
1,497
160
-
276
20,168
20,168		 Prior Year
Total
Funds
2021
£
5,100
720
544
3,078
653
1,237
28
1,715
435
10
2,840
9,766
157
3,593
329
30,205
30,205

39

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Detailed analysis of income and expenditure for the year ended 31 March 2022 as required by the SORP 2015

Support costs for charitable activities cont.

Prior Year
Recharged expenses
Support costs before reallocation
Total support costs - Prior Year
31. Other Expenditure - Governance costs
Current Year
Independent Examiner’s fees
Trustees’ expenses
Total Governance costs		 Current year
Unrestricted
Funds
2022
£
438
-
438		 Prior Year
Unrestricted
Funds
2022
£
781
29,271
29,271
Current year
Restricted
Funds
2022
£
-
-
-		 Prior Year
Restricted
Funds
2022
£
934
934
934
Current
year Total
Fund
2022
£
438
-
438		 Prior Year
Total Funds
2021
£
1,715
30,205
30,205
Prior Year
Total
Funds
2021
£
420
-
420

All the expenditure in the prior year was unrestricted.

40

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Detailed analysis of income and expenditure for the year ended 31 March 2022 as required by the SORP 2015

32. Total Charitable expenditure

Current Year
Total direct spending
B2a
Total grantmaking costs
B2c
Total support costs
B2d
Total Governance costs
B2e
Total charitable expenditure
B2
Prior Year
Total direct spending
Total grantmaking costs
Total support costs
Total Governance costs
Total charitable expenditure		 Current year
Unrestricted
Funds
2022
£
105,241
55,047
19,574
438
180,300
B2a
B2c
B2d
B2e
B2		 Current year
Restricted
Funds
2022
£
-
-
594
-
594
Prior Year
Unrestricted
Funds
2021
£
115,420
78,688
29,271
420
223,799		 Current year
Total Funds
2022
£
105,241
55,047
20,168
438
180,894
Prior Year
Restricted
Funds
2021
£
-
-
934
-
934		 Prior Year
Total Funds
2021
£
115,420
78,688
30,205
420
224,733
Prior Year
Total Funds
2021
£
115,420
78,688
30,205
420
224,733

41

Bath Institute for Rheumatic Diseases Supporting arthritis research, education and patient engagement

Annual Report and Accounts

31 March 2022

Company registration number 02908933 | Charity registration number 1040650